ABBV - AbbVie doses first patient in phase 3 trial of multiple myeloma asset
2024-06-05 10:10:34 ET
More on AbbVie
- AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)
- AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now
- Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
- Emerging and Chinese pharmas playing greater role in oncology drug development
- AbbVie wins EU backing for Skyrizi in bowel disorder